VisserFE, AldenkampAP, Van HuffelenAC, KuilmanM, OverwegJ, van WijkJ. Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am J Ment Retard, 1997; 101:400–412.
2.
WisniewskiKE, WisniewskiHM, WenGY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol, 1985; 17:278–282.
3.
RyeomS, FolkmanJ. Role of endogenous angiogenesis inhibitors in Down syndrome. J Craniofacial Surg, 2009; 20:595–596.
4.
RavindranathY, AbellaE, KrischerJP, WileyJ, InoueS, HarrisM, ChauvenetA, AlvaradoCS, DubowyR, RitcheyAKet al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood, 1992; 80:2210–2214.
5.
Al-KasimF, DoyleJJ, MasseyGV, WeinsteinHJ, ZipurskyA. Pediatric Oncology Group. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group study. J Pediatr Hematol Oncol, 2002; 24:9–13.
6.
HendersonA, LynchSA, WilkinsonS. Adults with Down's Syndrome: The prevalence of complications and health care in the community. Br J Gen Pract, 2007; 57:50–55.
7.
PueschelSM, LouisS, McKnightP. Seizure disorders in Down syndrome. Arch Neurol, 1991; 48:318–313.
8.
LottIT, DierssenM. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol, 2010; 9,623–633.
